The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 07, 2026

Filed:

Sep. 08, 2022
Applicant:

University of Maryland, College Park, College Park, MD (US);

Inventors:

Megan Kimicata, New Market, MD (US);

John Patrick Fisher, Kensington, MD (US);

Assignee:

University of Maryland, College Park, College Park, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61L 27/54 (2006.01); A61L 27/36 (2006.01); A61L 27/50 (2006.01); A61L 33/00 (2006.01); A61L 33/12 (2006.01); B33Y 80/00 (2015.01);
U.S. Cl.
CPC ...
A61L 27/54 (2013.01); A61L 27/3625 (2013.01); A61L 27/507 (2013.01); A61L 33/0011 (2013.01); A61L 33/124 (2013.01); B33Y 80/00 (2014.12);
Abstract

Current approaches in small diameter vascular grafts for coronary artery bypass surgeries fail to address physiological variations along the graft that contribute to thrombus formation and ultimately graft failure. An interlayer drug delivery system can sustain delivery of heparin through the graft with a high degree of temporal and spatial control. A heparin-loaded gelatin methacrylate interlayer sits between a biohybrid composed of decellularized bovine pericardium and poly(propylene fumarate) and UV crosslinking is controlled via 3D printed shadow masks. The masks enable control of the resultant gelMA crosslinking and properties by modulating the incident light intensity on the graft. High doses of heparin have detrimental effects on endothelial cell function. When exposed to heparin in a slower, more sustained manner consistent with the masks, endothelial cells behave similarly to untreated cells. Slower release profiles cause significantly more release of tissue factor pathway inhibitor, an anticoagulant, than a faster release profile.


Find Patent Forward Citations

Loading…